172 related articles for article (PubMed ID: 17456055)
1. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.
De Vita S; Mulligan C; McElwaine S; Dagna-Bricarelli F; Spinelli M; Basso G; Nizetic D; Groet J
Br J Haematol; 2007 May; 137(4):337-41. PubMed ID: 17456055
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
Sato T; Toki T; Kanezaki R; Xu G; Terui K; Kanegane H; Miura M; Adachi S; Migita M; Morinaga S; Nakano T; Endo M; Kojima S; Kiyoi H; Mano H; Ito E
Br J Haematol; 2008 May; 141(5):681-8. PubMed ID: 18397343
[TBL] [Abstract][Full Text] [Related]
3. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
4. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.
Nikolaev SI; Santoni F; Vannier A; Falconnet E; Giarin E; Basso G; Hoischen A; Veltman JA; Groet J; Nizetic D; Antonarakis SE
Blood; 2013 Jul; 122(4):554-61. PubMed ID: 23733339
[TBL] [Abstract][Full Text] [Related]
5. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
6. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
[TBL] [Abstract][Full Text] [Related]
7. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
8. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
9. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.
McElwaine S; Mulligan C; Groet J; Spinelli M; Rinaldi A; Denyer G; Mensah A; Cavani S; Baldo C; Dagna-Bricarelli F; Hann I; Basso G; Cotter FE; Nizetic D
Br J Haematol; 2004 Jun; 125(6):729-42. PubMed ID: 15180862
[TBL] [Abstract][Full Text] [Related]
10. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
11. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
12. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Riera L; Lasorsa E; Bonello L; Sismondi F; Tondat F; Di Bello C; Di Celle PF; Chiarle R; Godio L; Pich A; Facchetti F; Ponzoni M; Marmont F; Zanon C; Bardelli A; Inghirami G
Leuk Lymphoma; 2011 Sep; 52(9):1742-50. PubMed ID: 21599579
[TBL] [Abstract][Full Text] [Related]
13. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.
Hama A; Muramatsu H; Makishima H; Sugimoto Y; Szpurka H; Jasek M; O'Keefe C; Takahashi Y; Sakaguchi H; Doisaki S; Shimada A; Watanabe N; Kato K; Kiyoi H; Naoe T; Kojima S; Maciejewski JP
Br J Haematol; 2012 Feb; 156(3):316-25. PubMed ID: 22122069
[TBL] [Abstract][Full Text] [Related]
14. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
Kanegane H; Watanabe S; Nomura K; Xu G; Ito E; Miyawaki T
Int J Hematol; 2007 Oct; 86(3):250-2. PubMed ID: 17988992
[TBL] [Abstract][Full Text] [Related]
15. Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Walters DK; Mercher T; Gu TL; O'Hare T; Tyner JW; Loriaux M; Goss VL; Lee KA; Eide CA; Wong MJ; Stoffregen EP; McGreevey L; Nardone J; Moore SA; Crispino J; Boggon TJ; Heinrich MC; Deininger MW; Polakiewicz RD; Gilliland DG; Druker BJ
Cancer Cell; 2006 Jul; 10(1):65-75. PubMed ID: 16843266
[TBL] [Abstract][Full Text] [Related]
16. Activating mutations in human acute megakaryoblastic leukemia.
Malinge S; Ragu C; Della-Valle V; Pisani D; Constantinescu SN; Perez C; Villeval JL; Reinhardt D; Landman-Parker J; Michaux L; Dastugue N; Baruchel A; Vainchenker W; Bourquin JP; Penard-Lacronique V; Bernard OA
Blood; 2008 Nov; 112(10):4220-6. PubMed ID: 18755984
[TBL] [Abstract][Full Text] [Related]
17. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
18. The landscape of somatic mutations in Down syndrome-related myeloid disorders.
Yoshida K; Toki T; Okuno Y; Kanezaki R; Shiraishi Y; Sato-Otsubo A; Sanada M; Park MJ; Terui K; Suzuki H; Kon A; Nagata Y; Sato Y; Wang R; Shiba N; Chiba K; Tanaka H; Hama A; Muramatsu H; Hasegawa D; Nakamura K; Kanegane H; Tsukamoto K; Adachi S; Kawakami K; Kato K; Nishimura R; Izraeli S; Hayashi Y; Miyano S; Kojima S; Ito E; Ogawa S
Nat Genet; 2013 Nov; 45(11):1293-9. PubMed ID: 24056718
[TBL] [Abstract][Full Text] [Related]
19. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
20. Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).
Pelleri MC; Piovesan A; Caracausi M; Berardi AC; Vitale L; Strippoli P
BMC Med Genomics; 2014 Dec; 7():63. PubMed ID: 25476127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]